Eastman Chemical reported a decrease in sales revenue and EBIT in the third quarter of 2025, primarily due to lower sales volume/mix across all segments and reduced asset utilization. Despite these headwinds, the company delivered strong operating cash flow and made significant progress on inventory reduction, while maintaining stable prices in specialty businesses.
Sales revenue decreased by 11% to $2,202 million, driven by lower sales volume/mix and selling prices.
Adjusted EBIT was $210 million, down from $366 million in the prior-year quarter.
Net cash provided by operating activities was strong at $402 million, consistent with the prior year.
Adjusted earnings per diluted share were $1.14, a decrease from $2.26 in Q3 2024.
Eastman expects a greater than normal seasonal decline in volume in Q4 2025 due to challenging macroeconomic conditions, particularly in consumer discretionary markets. The company remains focused on cash flow, cost management, and expects price-cost stability. Full-year 2025 adjusted EPS is projected between $5.40 and $5.65, with operating cash flow approaching $1 billion.